Entyvio

Entyvio Dosage/Direction for Use

vedolizumab

Manufacturer:

Takeda

Distributor:

DKSH
Full Prescribing Info
Dosage/Direction for Use
Entyvio treatment should be initiated and supervised by specialist healthcare professionals experienced in the diagnosis and treatment of ulcerative colitis or Crohn's disease (see Precautions).
Ulcerative Colitis: The recommended dose regimen of Entyvio is 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter.
Continued therapy for patients with ulcerative colitis should be carefully reconsidered if no evidence of therapeutic benefit is observed by Week 10 (see Pharmacology: Pharmacodynamics under Actions).
Some patients who have experienced a decrease in their response may benefit from an increase in dosing frequency to Entyvio 300 mg every four weeks.
In patients who have responded to treatment with Entyvio, corticosteroids may be reduced and/or discontinued in accordance with standard of care.
Retreatment: If therapy is interrupted and there is a need to restart treatment with Entyvio, dosing at every four weeks may be considered (see Pharmacology: Pharmacodynamics under Actions). The treatment interruption period in clinical trials extended up to one year. Efficacy was regained with no evident increase in adverse events or infusion-related reactions during retreatment with vedolizumab (see Adverse Reactions).
Crohn's disease: The recommended dose regimen of Entyvio is 300 mg administered by intravenous infusion at zero, two and six weeks and then every eight weeks thereafter.
Patients with Crohn's disease, who have not shown a response may benefit from a dose of Entyvio at Week 10 (see Precautions). Continue therapy every eight weeks from Week 14 in responding patients. Therapy for patients with Crohn's disease should not be continued if no evidence of therapeutic benefit is observed by Week 14 (see Pharmacology: Pharmacodynamics under Actions).
Some patients who have experienced a decrease in their response may benefit from an increase in dosing frequency to Entyvio 300 mg every four weeks.
In patients who have responded to treatment with Entyvio, corticosteroids may be reduced and/or discontinued in accordance with standard of care.
Retreatment: If therapy is interrupted and there is a need to restart treatment with Entyvio, dosing at every four weeks may be considered (see Pharmacology: Pharmacodynamics under Actions). The treatment interruption period in clinical trials extended up to one year. Efficacy was regained with no evident increase in adverse events or infusion-related reactions during retreatment with vedolizumab (see Adverse Reactions).
Paediatric population: The safety and efficacy of vedolizumab in children aged 0 to 17 years old have not been established. No data are available.
Elderly patients: No dose adjustment is required in elderly patients. Population pharmacokinetic analyses showed no effect of age (see Pharmacology: Pharmacokinetics under Actions).
Patients with renal or hepatic impairment: Entyvio has not been studied in these patient populations. No dose recommendations can be made.
Method of administration: Entyvio is for intravenous use only. It is to be reconstituted and further diluted prior to intravenous administration, for instructions see Cautions for Usage.
Entyvio is administered as an intravenous infusion over 30 minutes. Patients should be monitored during and after infusion (see Precautions).
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in